List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Overview
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Aurigene Discovery Technologies Ltd
Beta Pharma Inc
Carrick Therapeutics UK Ltd
Cyclacel Pharmaceuticals Inc
Qurient Co Ltd
Syros Pharmaceuticals Inc
Tiziana Life Sciences Plc
Ube Industries Ltd
Yungjin Pharm Co Ltd
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles
BS-181L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-7001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapacitabine + seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Solid Tumor, Inflammation and Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SY-5609 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UD-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YPN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Dormant Products
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Discontinued Products
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: Syros presents new preclinical data on SY-5609, its highly selective oral CDK7 inhibitor, at AACR-NCI-EORTC International Conference
Oct 17, 2019: Syros announces update on oral CDK7 inhibitor SY-5609
Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data
Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-5609
Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial
Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Jun 03, 2019: Adastra Pharmaceuticals announces positive interim data from Phase 1b clinical trial of zotiraciclib in the treatment of recurrent malignant gliomas
May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
Apr 24, 2019: Tiziana reports encouraging interim clinical data from an ongoing phase 2a trial with milciclib in advanced liver cancer patients
Apr 17, 2019: Syros to host key opinion leader symposium on CDK7 Inhibitor SY-5609 on April 24, 2019
Apr 09, 2019: Yungjin Pharm announced a new targeted anti-cancer drug at AACR 2019
Apr 02, 2019: Syros presents preclinical data on SY-5609 at AACR 2019 annual meeting
Feb 27, 2019: Syros to present new preclinical data on its Selective CDK7 inhibitor SY-5609 at AACR Annual Meeting
Jan 06, 2019: Syros provides update on its oncology drug candidate SY-5609
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adastra Pharmaceuticals Inc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Beta Pharma Inc, H2 2019
Pipeline by Carrick Therapeutics UK Ltd, H2 2019
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
Pipeline by Qurient Co Ltd, H2 2019
Pipeline by Syros Pharmaceuticals Inc, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Pipeline by Ube Industries Ltd, H2 2019
Pipeline by Yungjin Pharm Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019

Companies Mentioned
• Adastra Pharmaceuticals Inc
• Aurigene Discovery Technologies Ltd
• Beta Pharma Inc
• Carrick Therapeutics UK Ltd
• Cyclacel Pharmaceuticals Inc
• Qurient Co Ltd
• Syros Pharmaceuticals Inc
• Tiziana Life Sciences Plc
• Ube Industries Ltd
• Yungjin Pharm Co Ltd